The field of chimeric antigen receptor (CAR) modified T cell therapy has rapidly expanded in
the past few decades. As of today, there are six CAR T cell products that have been …

In recent years, Bruton tyrosine kinase (BTK) inhibitors have provided significant advances
in the treatment of patients with B-cell malignancies. Ibrutinib was the first BTK inhibitor to be …

Current limitations in using chimeric antigen receptor T (CART) cells to treat patients with
hematological cancers include limited expansion and persistence in vivo that contribute to …

Chimeric antigen receptor (CAR)-mediated targeting of T lineage antigens for the therapy of
blood malignancies is frequently complicated by self-targeting of CAR T cells or their …

Chimeric antigen receptor T (CAR-T) cell therapy has significantly improved the life
expectancy for patients with refractory or relapse B cell lymphoma. As for B cell acute …

CART19 cells are emerging as an alternative therapy for patients with chronic lymphocytic
leukemia (CLL). Here we report the outcome of nine consecutive patients with CLL treated …

Chimeric antigen receptor-T cell therapy, a groundbreaking cancer treatment, has achieved
remarkable success against hematologic malignancies. However, CAR-T monotherapy …

Chimeric antigen receptor (CAR) T cell therapy has revolutionized the therapeutic
landscape of haematological malignancies. However, resistance and relapse remain …

Opinion statement Although chimeric antigen receptor T cell immunotherapy has been
successfully applied in patients with hematological malignancies, several obstacles still …

The clinical success of the two BTK inhibitors, ibrutinib and acalabrutinib, represents a major
breakthrough in the treatment of chronic lymphocytic leukemia (CLL) and has also …